Will Bolus for Beignets - Part 2: Candid Conversations from ADA

Hosted by Nancy Hanna and Dena Gottesman

The guests on this episode have an ongoing commercial relationship with Insulet, and Insulet has paid a fee for their participation in this podcast.

In the second part of this episode, Nancy and Dena continue with impromptu interviews of attendees at the 82nd ADA conference. These talks include topics such as the accessibility of new diabetes treatment technology with Dr. Osama Hamdy, helping patients achieve their diabetes goals with individualized care with Jeremy Beaulieu, glucose testing practices with Clinical Professor in Medicine Dr. Edward Chao, as well as a conversation with this year’s Outstanding Physician Clinician in Diabetes Award winner, Dr. Janet McGill.

Time stamps

00:51 – Learn about the evolution of diabetes technology and the impact on people with diabetes from Dr. Osama Hamdy, MD, Joslin Diabetes Center
6:32 – Dr. Janet McGill, Washington University in Saint Louis, discusses her visions for the future of diabetes care
13:40 – Dr. Edward Chao, University of California San Diego, talks about non-invasive glucose testing, design thinking, the user perspective and how it can be applied to improve patient care and help solve pain points
17:40 – Jeremy Beaulieu, Nurse Practitioner and CDCES discusses how to help patients reach their diabetes goals.

 

See more episodes
This podcast provides general information and discussions about health and related subjects. This information and other content provided in this podcast, or in any linked materials, are not intended and should not be construed as medical advice, nor is the information a substitute for professional medical expertise or treatment. If you or any other person has a medical concern, you should consult your health care provider or seek other professional medical treatment. Never disregard professional medical advice or delay in seeking it because of something that you have heard in this podcast or read in any linked materials. The opinions and views expressed on this podcast and website have no relation to those of any academic, hospital, health practice or other institution.

Please consult the Omnipod® 5 Automated Insulin Delivery System User Guide for more information.

The Omnipod 5 Automated Insulin Delivery System is a single hormone insulin delivery system intended to deliver U-100 insulin subcutaneously for the management of type 1 diabetes in persons aged 2 and older & type 2 diabetes in persons aged 18 years and older. The Omnipod 5 System is intended for single patient use. The Omnipod 5 System is indicated for use with NovoLog®, Humalog®, and Admelog®. Refer to the Omnipod 5 Automated Insulin Delivery System User Guide and www.omnipod.com/safety for complete safety information including indications, contraindications, warnings, cautions, and instructions. Warning: DO NOT use SmartAdjust technology for individuals under 2 years of age or use less than 5 U of insulin per day. DO NOT start to use the Omnipod 5 System or change settings without adequate training and guidance from a healthcare provider. Initiating and adjusting settings incorrectly can result in over-delivery or under-delivery of insulin, which could lead to hypoglycemia or hyperglycemia.